Sex-specific effect of body weight gain on systemic inflammation in subjects with COPD: results from the SAPALDIA cohort study 2

P-O. Bridevaux, M. W. Gerbase, C. Schindler, D. Felber Dietrich, I. Curjuric, J. Dratva, U. Ackermann-Liebrich, N. M. Probst-Hensch, J-M. Gaspoz, T. Rochat
European Respiratory Journal 2009 34: 332-339; DOI: 10.1183/09031936.00162608

Abstract

Systemic inflammation may mediate the association between chronic obstructive pulmonary disease (COPD) and extrapulmonary comorbidities. We measured high-sensitivity C-reactive protein (hs-CRP) in COPD and quantified the effect modification by body weight change and sex.

Using data from the Swiss study on Air Pollution and Lung Diseases in Adults (SAPALDIA; n = 5,479) with measurements of forced expiratory volume in 1 s (FEV1), body weight and hs-CRP, we examined the association of hs-CRP and categories of body weight change (lost weight and weight gained 0–5%, 5–9%, 9–14% and >14%) with fast FEV1 decline.

hs-CRP was elevated both in association with fast FEV1 decline and body weight gain. Subjects with fast FEV1 decline and weight gain (>14%) had higher hs-CRP (2.0 mg·L−1 for females versus 1.6 mg·L−1 for males). After adjustment for age, smoking, physical activity, hormonal therapy and diabetes, elevated hs-CRP (>3 mg) was found to be more likely in subjects with fast FEV1 decline (ORmales 1.38, ORfemales 1.42) and in those with weight gain >14% (ORmales 2.04, ORfemales 4.51).

The association of weight gain and fast FEV1 decline predicts a higher level of systemic inflammation. Since the effect of weight gain on systemic inflammation is larger in females than in males, weight gain may be a risk factor for extrapulmonary comorbidities in females with COPD.

Worldwide, chronic obstructive pulmonary disease (COPD) is a prevalent disease which is projected to become the fourth leading cause of death by 2020 1, although most patients with COPD are classified into the mild or moderate categories according to recent studies 2, 3. COPD prevalence and related mortality are increasing in females: in 2000, females dying with COPD outnumbered males dying with the condition in the USA 4. Females may have increased susceptibility to COPD and, once the disease is established, its prognosis may be worse for them, even after adjustments for smoking, forced expiratory volume in 1 s (FEV1) and age 5, 6. This phenomenon remains unexplained.

Inflammatory processes related to COPD extend beyond the lungs and explain a higher level of systemic inflammation, as measured by high-sensitivity C-reactive protein (hs-CRP), fibrinogen, tumour necrosis factor-α, leukocytes, and interleukin-6 or -8 7. In fact, systemic inflammation may contribute to the diverse extrapulmonary comorbidities frequently seen in COPD patients, such as skeletal muscle wasting or cardiovascular disease 8, 9, for which COPD is an independent risk factor 10. Indeed, a leading cause of death in COPD includes cardiovascular disease, which is more frequent than respiratory failure in mild or moderate disease 11.

hs-CRP, a marker of systemic inflammation, is increased in association with several factors, such as smoking, diabetes or obesity 12, 13. Conversely, physical activity, smoking cessation or dietary interventions may reduce hs-CRP and have been associated with slower lung function decline 14–16. Elevated CRP (>3 mg·L−1) is strongly associated with cardiovascular morbidity and mortality, and it has been hypothesised that systemic inflammation mediates the relationship between mild COPD and cardiovascular mortality 9, 17, 18. Thus, reducing systemic inflammation and, hence, cardiovascular morbidity and mortality would be a major objective of COPD management. Observational studies suggest that statins may decrease serum levels of hs-CRP and have a protective effect independent of the effect on lipid metabolism in COPD patients 19. To date, however, no single medication has proved to be efficacious in reducing mortality in patients with COPD. This suggests that the multiple origins of systemic inflammation in COPD (e.g. obesity, smoking or lung inflammation) need to be better understood in order to propose efficient therapeutic interventions. As the prevalence of obesity is growing, a cumulative effect of COPD and obesity on systemic inflammation is possible.

It is unknown whether the excess of death related to COPD in females, as described in previous studies, could be related to higher levels of systemic inflammation compared with males 4. The aim of the present study was to examine the complex relationship between weight gain and systemic inflammation in subjects with COPD, as defined by fast FEV1 decline. Specifically, we sought to determine whether body weight gain modifies systemic inflammation in COPD and, if so, whether this effect is different in males and females.

METHODS

Study population

The Swiss study on Air Pollution and Lung Diseases in Adults (SAPALDIA) cohort was initiated in 1991 to assess the effect of air pollution on respiratory health in Switzerland. Detailed descriptions of the cohort can be found elsewhere 20–22. Briefly, in 1991, 9,651 randomly selected adults in eight geographically and culturally diverse areas (Basel, Aarau, Geneva, Montana, Davos, Wald, Payerne and Lugano) were included and followed for, on average, 10.9 yrs. Of those subjects, 8,876 had pulmonary function tests (PFTs). In 2002, the follow-up study enrolled 8,047 (83.4%) subjects from the 1991 sample. For the present study, we included subjects who had PFTs at both surveys (SAPALDIA 1 in 1991 and SAPALDIA 2 in 2002), and who provided blood for hs-CRP measurements in 2002. We excluded 187 subjects in whom elevated hs-CRP (>10 mg·L−1) could be related to a current infection (fig. 1⇓).

Fig. 1—
Fig. 1—

Flow chart of participants included in the present Swiss study on Air Pollution and Lung Diseases in Adults (SAPALDIA; 1991–2002). PFTs: pulmonary function tests; hs-CRP: high-sensitivity C-reactive protein; FEV1: forced expiratory volume in 1 s. #: upper quartile of FEV1 decline (% baseline FEV1).

Pulmonary function tests

PFTs were performed according to the American Thoracic Society standards, using the same spirometers (SensorMedics 2200 SP; Yorba Linda, CA, USA) at both surveys. This was done in order to limit systematic bias error in volume measurement 23. FEV1 and forced vital capacity (FVC) were obtained without bronchodilators. We used the European Respiratory Society equation to calculate the predicted values of FEV1 and FVC 24. FEV1 decline was calculated as the difference between the two measurements divided by the baseline (1991) FEV1. Each subject was classified into a quartile of FEV1 decline and those in the highest quartile were defined as fast decliners. This definition of COPD was chosen because the rate of FEV1 decline is a key marker of COPD 25.

Weight change

Weight and height were recorded immediately before PFTs. Body weight change was calculated as the difference in weight between the two surveys divided by baseline (1991) weight. Body weight change was divided into five groups: 1) the “weight loss” group included subjects who lost ≥0.1% of their baseline weight between the two surveys; 2) the “gained ≤5%” group encompassed subjects whose weight change was between 0% and ≤5%; 3) the “gained ≤9%” group had weight change between >5% and ≤9%; and 4) the “gained ≤14%” and 5) “gained >14%” groups corresponded to a weight gain of >9% to ≤14% and >14%, respectively. Categories of weight change were chosen such as to examine a wide range of individual weight changes while preserving sufficient numbers of subjects in each category.

Covariates

Smoking status (current, former or never-smoker) and lifetime smoking (packs of cigarettes per day × smoking duration (yrs)) were recorded at both surveys.

The level of physical activity was assessed at SAPALDIA 2 with questions addressing the frequency and the intensity of physical activity. Results of these questions were combined into a single variable that defined subjects as “physically active” if they fulfilled the following criteria: 1) exercise for ≥1 h·week−1 and 2) twice or more times per week. Categorisation of physical activity into two broad groups is in accordance with published literature 26, 27. For detailed questions and subjects’ classification, see the online supplementary material. Highest education reached, use of hormone replacement therapy and comorbid conditions were self-reported and extracted from the questionnaire administered by trained interviewers.

hs-CRP

Serum hs-CRP was determined at SAPALDIA 2 (2002) from frozen serum by the Institute for Clinical Chemistry of the University Hospital Zürich, Switzerland, using a new latex-enhanced immunoturbidimetric assay (Roche Diagnostics, Mannheim, Germany).

Statistical analyses

Statistical analyses were carried out with Stata version 10 (StataCorp, College Station, TX, USA). As the main variable of interest, hs-CRP, was not normally distributed, it was log-transformed and described by its geometric mean. Predictors of interest were body weight change categories in subjects with or without fast FEV1 decline. Linear regression models were used to investigate the relationship between body weight change categories and log-transformed hs-CRP in subjects with or without fast FEV1 decline.

We tested the interactions between fast FEV1 decline and the following variables: weight change (continuous variable or group variable), smoking status, physical activity and hormonal therapy. For the purpose of the analyses and according to the published literature, we dichotomised hs-CRP into a low and high hs-CRP level (>3 mg·L−1). Logistic regression was applied to measure the association between fast FEV1 decline, weight change groups and high hs-CRP (dependent variable). Hosmer and Lemeshow goodness-of-fit tests were performed. Adjustments were made for age, age squared, smoking status, lifetime smoking (pack-yrs), physical activity, diabetes and study area as a random effect variable. In females, hormone replacement therapy was also included in the models.

Sensitivity analysis

All analyses were repeated with the following changes. First, subjects with hs-CRP ≥10 mg·L−1 were included. Secondly, subjects with a restrictive pattern (FEV1/FVC ratio ≥0.7 and FVC <80% predicted) were excluded. Thirdly, the following potential confounders were included in the models: physician-diagnosed asthma, hypertension, cardiac disease or education level. Fourthly, absolute body weight change and absolute FEV1 decline were used as predictors of hs-CRP instead of relative changes. Fifthly, we restricted the definition of COPD further by adding the mandatory presence of respiratory symptoms (chronic cough, phlegm or shortness of breath by walking) to the group of subjects with fast FEV1 decline. Sixthly, we also tested our models using the modified (without bronchodilation) Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2–4 category to define COPD and, seventhly, using modified GOLD 1–4 definition and fast FEV1 decline as predictor.

RESULTS

Of the 6,215 adult participants who had PFTs at both SAPALDIA 1 and 2, 5,666 (91.1%) had determination of hs-CRP. Characteristics of the subjects by sex and FEV1 decline are shown in table 1⇓ and in the online supplementary material. Fast FEV1 decline was associated with older age, lower education, higher smoking exposure, higher FEV1 at baseline, more symptoms and lower health-related quality of life. Males with fast FEV1 decline reported hypertension and cardiac disease more frequently. At follow-up, weight gain was larger for fast FEV1 decliners. The mean yearly FEV1 losses were three times larger among fast FEV1 decliners compared with non-fast decliners. Abnormal FEV1/FVC ratio (i.e. <0.7) according to the GOLD criterion was met in 46.0% of males and 36.1% of females with fast FEV1 decline versus 17.4% and 12.8%, respectively, in non-fast FEV1 decliners.

View this table:
Table 1—

Subject characteristics by categories of forced expiratory volume in 1 s(FEV1) decline in the Swiss study on Air Pollution and Lung Diseases in Adults (SAPALDIA)

Associations between weight change categories, FEV1 decline and hs-CRP

Overall, age-adjusted (age 52 yrs) geometric means of hs-CRP concentrations were 1.15 mg·L−1 (95% CI 1.11–1.20) for females and 1.06 mg·L−1 (95% CI 1.01–1.11) for males (Wilcoxon rank-sum test: p = 0.002). In both sexes, before stratification by body weight change categories, subjects with fast FEV1 decline had higher age-adjusted hs-CRP compared with subjects without fast FEV1 decline (table 2⇓). A positive association between body weight change categories and hs-CRP was observed. However, this relationship was more pronounced in females. Overall, males and females with fast FEV1 decline had higher hs-CRP in all categories of body weight change. No statistically significant interactions between fast FEV1 decline and weight change categories were found. Table 2⇓ further shows that current smoking, lack of physical activity and hormone replacement therapy were all associated with higher hs-CRP. Interaction between current smoking and fast FEV1 decline was found in females, but not in males.

View this table:
Table 2—

Age-adjusted high-sensitivity C-reactive protein (hs-CRP) concentration (mg·L−1) for non-fast and fast forced expiratory volume in 1 s (FEV1) decliners

Baseline body mass index (1991), which was weakly correlated with weight change in males (R2 = 0.0124; p<0.001) and not correlated in females (R2 = 0.0007; p = 0.120), was not a predictor of systemic inflammation at SAPALDIA 2 (2002).

Figure 2⇓ shows the probability of elevated hs-CRP (>3 mg·L−1) in males and females with or without fast FEV1 decline as a function of weight change. Subjects with fast FEV1 decline had higher probability of elevated hs-CRP compared with controls. Body weight increase was also associated with a higher probability of elevated hs-CRP. Figure 2⇓ also indicates that the effect of weight gain was much more pronounced in females than in males. Subjects with GOLD stage 2–4 COPD were more likely to be in the fast decliner categories of both sexes. The Hosmer and Lemeshow test was nonsignificant, indicating adequate model fit.

Fig. 2—
Fig. 2—

Probability of elevated high-sensitivity C-reactive protein (hs-CRP) as a function of weight change in males and females. •: females, fast forced expiratory volume in 1 s (FEV1) decline; ○: females, non-fast FEV1 decline; ▪: males, fast FEV1 decline; □: males, non-fast FEV1 decline; grey symbols: fast FEV1 decline, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages 2–4 chronic obstructive pulmonary disease. For interaction between fast FEV1 decline and weight change, p = 0.513; for interaction between sex and weight change, p = 0.012.

Table 3⇓ shows the unadjusted and adjusted odds ratios of high hs-CRP for males and females. For both sexes, fast FEV1 decline and weight gain were associated with high hs-CRP. Weight loss was negatively associated with high hs-CRP in males but not in females. Overall, the relationship between high hs-CRP and weight gain or fast FEV1 decline was stronger and more significant in females than in males. For example, females with fast FEV1 decline and weight gain >14% were 4.5 times more likely to have hs-CRP >3 mg·L−1 than females with stable weight. Males with fast FEV1 decline and similar weight gain were only twice as likely to have elevated hs-CRP. When controlling for weight change categories and other covariates, females with fast FEV1 decline had a 31% increase in probability of elevated hs-CRP, whereas males had a smaller (25%) and not statistically significant increase. Sensitivity analyses with different definitions of COPD are displayed in the online supplementary material.

View this table:
Table 3—

ORs and 95% CIs of high level of high-sensitivity C-reactive protein (hs-CRP; >3 mg) in subjects of the Swiss study on Air Pollution and Lung Diseases in Adults (SAPALDIA)

Sensitivity analyses

The relationship between weight change and hs-CRP was not modified by inclusion of subjects with hs-CRP ≥10 mg·L−1 (females, n = 96; males, n = 91). It was modified neither when subjects with restrictive physiology (n = 33) were excluded nor when covariates such as diabetes, hypertension, cardiac disease, physician-diagnosed asthma or education level were added. Association between hs-CRP and weight change and FEV1 decline categories were amplified when absolute values of FEV1 decline and weight change were used. Interpretations of the data were unchanged when the definition of COPD was restricted as shown in the online supplementary material (fifth to seventh sensitivity analysis).

DISCUSSION

In this 11-yr cohort study, we found that the associated effects of weight gain and fast FEV1 decline predicted a greater systemic inflammation, as measured by hs-CRP, in females compared with males. This association persisted after controlling for common predictors of systemic inflammation, such as age, smoking, hormonal replacement therapy or physical activity. We hypothesised that fast FEV1 decline and weight gain would interact to increase systemic inflammation. We found that fast FEV1 decline and weight increase are independent predictors of systemic inflammation and more so in females. This finding is robust and insensitive to COPD definition or to exclusion of subjects with restrictive physiology.

The rate of FEV1 decline among fast FEV1 decliners appears larger in our cohort compared with recent clinical trials on COPD, whereas it is similar to other population studies among non-fast FEV1 decliners 28–30. Several factors may explain this. First, our definition captured subjects in the upper quartile of FEV1 decline where the distribution of FEV1 decline is skewed. This provides a first explanation for the high mean value in this group. Secondly, the generally high FEV1 values at baseline in our population sample allow for larger absolute values of decline. Given the large differences in rate of decline between non-fast and fast FEV1 decliners and the considerable length of follow-up, misclassification of fast FEV1 decline is unlikely.

The level of hs-CRP in our subjects with fast FEV1 decline is concordant with recent studies reporting various biomarkers of inflammation including CRP, despite a different definition of COPD (GOLD stage 2 criteria versus fast FEV1 decline) 31. In a population study, Sin and Man 32 showed that moderate and severe COPD were associated with high CRP. They also found that signs of myocardial ischaemia on electrocardiographic studies correlated with systemic inflammation 32. Others found that raised CRP was a marker of disease severity in patients with COPD 33. Our study complements these findings and shows that level of hs-CRP in subjects with accelerated FEV1 decline is sex specific and dependent on weight gain. At the other end of the spectrum of weight change, we found a trend towards higher systemic inflammation in females with fast FEV1 decline and weight loss (table 3⇑). Weight loss in females, but not in males, was associated with lower health status and higher healthcare utilisation (data not shown). This suggests that the effect of weight loss in females with COPD is a consistent marker of poor outcome, whereas the heterogeneity of causes leading to weight loss in males precludes further conclusion.

A similar association was previously described by Fogarty et al. 34, who found that subjects with low body mass index (<20 kg·m−2) and low FEV1 had a higher level of systemic inflammation.

There are multiple factors that could explain the different levels of systemic inflammation in males and females with COPD. Higher systemic inflammation in females with COPD and weight gain may be due to a higher release of pro-inflammatory factors, such as interleukin-6, from adipose tissue or from damaged lung. This first explanation would be in line with a large population study showing that the association between CRP and obesity was stronger in females than in males 35. Oestrogen or progesterone substitutive therapies have also been described as factors stimulating hs-CRP 36. Also possible is a higher rate of production of pro-inflammatory cytokines by the lung exposed to cigarette smoking in females (assuming a similar level of exposure in males). This suggests an increased susceptibility to the effects of smoking in females. Other plausible explanations for the higher level of systemic inflammation in females with COPD and weight gain are: 1) a relatively lower level of physical activity or 2) a lower use of alcohol. For example, a study showing that moderate intake of alcohol was associated with lower level of systemic inflammation found less-frequent drinking of alcohol in females than in males 37. In our study, we were able to control for cigarette smoking and level of physical activity, which suggests that these factors do not fully explain the observed sex differences in levels of systemic inflammation.

From a pathophysiological point of view, the higher systemic inflammation measured in females with weight gain and COPD is relevant because it may partly explain why females with COPD seem to fare worse than males in terms of mortality 5. Systemic inflammation may play an independent role in the pathogenesis of cardiovascular disease or diabetes, as shown in large population studies of females 38, 39. In one study, hs-CRP was a stronger predictor of incident cardiovascular events than traditional risk factors in females 38. Future epidemiological studies measuring systemic inflammation, weight gain and incident cardiovascular events in subjects with mild or moderate COPD are needed to provide evidence that females with COPD experience worse outcomes because of higher levels of systemic inflammation and not because of other factors. These studies would also allow the determination of comorbid conditions that are amenable to therapy. For example, inhaled corticosteroids or statins decreased CRP 40, 41, whereas tiotropium had no effect on systemic inflammation 42. Through diminution of systemic inflammation, statins may reduce FEV1 decline 43. Also, statin therapy reduces cardiovascular mortality in males and females with abnormal CRP but low cholesterol levels 44. We show herein that the subgroup of females with weight gain and fast FEV1 decline have particularly high levels of hs-CRP. Due to the high probability of an elevated CRP value in this subgroup of females, the measurement of hs-CRP in this target population might help to better predict incident cardiovascular events.

Strengths of our analysis include the size of the population, which is an unbiased sample of the Swiss population, and standardised assessment of FEV1 and other covariates, such as hormonal therapy or physical activity.

Potential limitations are related to the absence of repeated measures of hs-CRP and body weight during the follow-up period. Due to potential confounding by respiratory infections, we excluded subjects with high hs-CRP; however, residual confounding is possible. Inclusion of these subjects (n = 187) in the analyses did not modify our estimates. Reverse causation (systemic inflammation causing FEV1 decline or weight change) cannot be formally excluded by our study design. Longitudinal studies with repeated measures of weight, FEV1, hs-CRP and incident cardiovascular or respiratory events may bring a more definite answer.

In summary, our results show that COPD, approximated by fast FEV1 decline, and weight gain are independent predictors of systemic inflammation with an exposure–response relationship. Notably, the relationship is sex specific: weight gain in subjects with COPD is more strongly associated with high hs-CRP in females than in males. These results may stimulate interventional studies specifically aimed at weight control among females with COPD.

Support statement

The SAPALDIA cohort study is supported by the Swiss National Science Foundation (grants 4026-28099, 3347CO-108796, 3247BO-104283, 3247BO-104288, 3247BO-104284, 32-65896.01, 32-59302.99, 32-52720.97, 32-4253.94), the Federal Office for Forest, Environment and Landscape, the Federal Office of Public Health, the Federal Office of Roads and Transport, the Canton's Government of Aargau, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Zürich, the Swiss Lung League, the Canton's Lung League of Basel Stadt/Basel Landschaft, Geneva, Ticino and Zürich.

Statement of interest

None declared.

Acknowledgments

The SAPALDIA team consists of the following. Study directorate: T. Rochat, U. Ackermann-Liebrich, J.M. Gaspoz, P. Leuenberger, L.J.S. Liu, N.M. Probst-Hensch and C. Schindler. Scientific team: J.C. Barthélémy, W. Berger, R. Bettschart, A. Bircher, O. Brändli, M. Brutsche, L. Burdet, M. Frey, M.W. Gerbase, D. Gold, W. Karrer, R. Keller, B. Knöpfli, N. Künzli, U. Neu, L. Nicod, M. Pons, E. Russi, P. Schmid-Grendelmeyer, J. Schwartz, P. Straehl, J.M. Tschopp, A. von Eckardstein, J.P. Zellweger and E. Zemp Stutz. Scientific collaborators at coordinating centres: P-O. Bridevaux, I. Curjuric, D. Felber Dietrich, A. Gemperli, M. Imboden, D. Keidel and P. Städele-Kessler.

We are indebted to the study participants, the technical and administrative support at coordinating centres, and the medical teams and field workers at the local study sites.

Footnotes

  • This article has supplementary material accessible from www.erj.ersjournals.com

    For editorial Comments see page 291.

  • Received October 28, 2008.
  • Accepted February 9, 2009.

References

  1. ↵
    Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997;349:1498–1504.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370:741–750.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Menezes AM, Perez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005;366:1875–1881.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. Respir Care 2002;47:1184–1199.
    OpenUrlPubMed
  5. ↵
    Machado MC, Krishnan JA, Buist SA, et al. Sex differences in survival of oxygen-dependent patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:524–529.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Chapman KR. Chronic obstructive pulmonary disease: are women more susceptible than men?. Clin Chest Med 2004;25:331–341.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574–580.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Agusti AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347–360.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Man SF, Connett JE, Anthonisen NR, et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006;61:849–853.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Zureik M, Kauffmann F, Touboul PJ, et al. Association between peak expiratory flow and the development of carotid atherosclerotic plaques. Arch Intern Med 2001;161:1669–1676.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005;128:2640–2646.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499–511.
    OpenUrlFREE Full Text
  13. ↵
    Greenfield JR, Samaras K, Jenkins AB, et al. Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation 2004;109:3022–3028.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among US adults. Epidemiology 2002;13:561–568.
    OpenUrlCrossRefPubMedWeb of Science
  15. Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med 2007;175:458–463.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    Nicklas BJ, You T, Pahor M. Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training. CMAJ 2005;172:1199–1209.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–843.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    Clarke R, Emberson JR, Breeze E, et al. Biomarkers of inflammation predict both vascular and non-vascular mortality in older men. Eur Heart J 2008;29:800–809.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47:2554–2560.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    Ackermann-Liebrich U, Kuna-Dibbert B, Probst-Hensch NM, et al. Follow-up of the Swiss Cohort Study on Air Pollution and Lung Diseases in Adults (SAPALDIA 2) 1991–2003: methods and characterization of participants. Soz Praventivmed 2005;50:245–263.
    OpenUrlCrossRefPubMedWeb of Science
  21. Martin BW, Ackermann-Liebrich U, Leuenberger P, et al. SAPALDIA: methods and participation in the cross-sectional part of the Swiss Study on Air Pollution and Lung Diseases in Adults. Soz Praventivmed 1997;42:67–84.
    OpenUrlPubMedWeb of Science
  22. ↵
    Downs SH, Schindler C, Liu LJ, et al. Reduced exposure to PM10 and attenuated age-related decline in lung function. N Engl J Med 2007;357:2338–2347.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    Kunzli N, Kuna-Dibbert B, Keidel D, et al. Longitudinal validity of spirometers – a challenge in longitudinal studies. Swiss Med Wkly 2005;135:503–508.
    OpenUrlPubMedWeb of Science
  24. ↵
    Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993;6: Suppl. 16 5–40.
    OpenUrlFREE Full Text
  25. ↵
    Fletcher CM, Peto R, Tinker CM, et al. The Natural History of Chronic Bronchitis and Emphysema. Oxford, Oxford University Press, 1976
  26. ↵
    Shaaban R, Leynaert B, Soussan D, et al. Physical activity and bronchial hyperresponsiveness: European Community Respiratory Health Survey II. Thorax 2007;62:403–410.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Nystad W, Samuelsen SO, Nafstad P, et al. Association between level of physical activity and lung function among Norwegian men and women: the HUNT study. Int J Tuberc Lung Dis 2006;10:1399–1405.
    OpenUrlPubMedWeb of Science
  28. ↵
    Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775–789.
    OpenUrlCrossRefPubMedWeb of Science
  29. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543–1554.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    Viegi G, Pistelli F, Sherrill DL, et al. Definition, epidemiology and natural history of COPD. Eur Respir J 2007;30:993–1013.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Walter RE, Wilk JB, Larson MG, et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest 2008;133:19–25.
    OpenUrlCrossRefPubMed
  32. ↵
    Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514–1519.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Broekhuizen R, Wouters EF, Creutzberg EC, et al. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006;61:17–22.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Fogarty AW, Jones S, Britton JR, et al. Systemic inflammation and decline in lung function in a general population: a prospective study. Thorax 2007;62:515–520.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131–2135.
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    Rexrode KM, Pradhan A, Manson JE, et al. Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol 2003;13:674–682.
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    Volpato S, Pahor M, Ferrucci L, et al. Relationship of alcohol intake with inflammatory markers and plasminogen activator inhibitor-1 in well-functioning older adults: the Health, Aging, and Body Composition study. Circulation 2004;109:607–612.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557–1565.
    OpenUrlCrossRefPubMedWeb of Science
  39. ↵
    Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327–334.
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:760–765.
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64–70.
    OpenUrlCrossRefPubMedWeb of Science
  42. ↵
    Powrie DJ, Wilkinson TM, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007;30:472–478.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 2007;176:742–747.
    OpenUrlCrossRefPubMedWeb of Science
  44. ↵
    Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195–2207.
    OpenUrlCrossRefPubMedWeb of Science
Back to top
View this article with LENS
Email
Print
Alerts
Citation Tools

Sex-specific effect of body weight gain on systemic inflammation in subjects with COPD: results from the SAPALDIA cohort study 2
P-O. Bridevaux, M. W. Gerbase, C. Schindler, D. Felber Dietrich, I. Curjuric, J. Dratva, U. Ackermann-Liebrich, N. M. Probst-Hensch, J-M. Gaspoz, T. Rochat
European Respiratory Journal Aug 2009, 34 (2) 332-339; DOI: 10.1183/09031936.00162608
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To